Both in Pharmaceuticals
Rezolute, Inc. Common Stock (NV) vs Lyell Immunopharma
Over the past year RZLT returned −55.5% and LYEL returned −3.3%; their daily moves had a correlation of 0.01.
RZLT −55.5% LYEL −3.3%Growth of $1, one year, split-adjusted
| Metric | RZLT | LYEL |
|---|---|---|
| Price | $3.96 | $15.43 |
| Market cap | $383.0M | $378.1M |
| Today | −1.25% | +43.27% |
| 1 month | −8.3% | +79.2% |
| 6 months | +26.1% | −26.0% |
| Year to date | +67.8% | −49.9% |
| 1 year | −56.5% | −6.8% |
| Revenue growth (YoY) | — | −50.0% |
| Gross margin | — | 100.0% |
| Net margin | — | −1118875.0% |
| P/E (TTM) | — | — |
| Price / sales | — | 14,004.2× |
| Net cash | $107.8M | $204.1M |
| Dividend yield | — | — |
| Volatility (60d) | 60.1% | 101.1% |
| Short % of float | 22.5% | 15.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).